Eyeworld

N EWS PRESENTATION SPOTLIGHT 28 | EYEWORLD | SEPTEMBER 2019 Contact information Al-Rahman: omneyaabdalrahman@gmail.com by Stefanie Petrou Binder, MD EyeWorld Contributing Writer Case studies Dr. Al-Rahman presented four case studies in which PRP injection was effective in lowering IOP. The first case involved a 55-year-old man with Axenfeld-Rieger syndrome. Due to elevat- ed IOP that was resistant to all anti-glaucoma eye drops, the patient underwent glaucoma surgery with express microvalve implantation and mitomycin-C enhancement. Hypotony en- sued as a result of scleral atrophy, overfiltration, and a leaky conjunctival bleb, due to anterior segment dysgenesis. Dr. Al-Rahman injected 0.3 ml autologous PRP intracamerally in an attempt to close the E ye platelet rich plasma (E-PRP) can lead to dramatic decreases in IOP in patients of different ages, genders, and with ocular hypotension of various etiologies, according to a presentation given at the 23rd European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting. Data indicate that platelet rich plasma can be a reliable and effective therapeutic tool to enhance epithelial wound healing in ocular surface disease. Blood derived products have demonstrated their capacity to enhance and stimulate the regeneration of different tissues. Eye platelet rich plasma provides a higher con- centration of essential growth factors and cell adhesion molecules by concentrating platelets in a small volume of plasma as compared to autologous serum, the latter being used widely in ophthalmology for epithelial wound healing of the cornea. 1 Autologous platelet treatment New evidence suggests that autologous platelet rich plasma injection into the anterior cham- ber may offer a new, promising technique for the treatment of progressive and severe oc- ular hypotony. E-PRP is prepared by means of a simple procedure involving collecting blood from the patient, separating the platelets through centrifugation, and extracting platelet rich growth factor for 3–6 mg of PRP. "PRP is a blood derived product that en- hances wound healing, stimulates tissue regen- eration, and allows better cell adhesion. E-PRP is safe to use in the anterior chamber," said Omneya Al-Rahman, MD, said, in her presenta- tion "Extreme ocular hypotension treated with platelet rich plasma." "Autologous blood has no risk of infection, no allergic reactions, or other side effects. It is convenient, quick, and non- invasive. PRP is natural, incurring no sense of violation from foreign body effect. And most importantly, it is effective in lowering IOP, with superior and long-lasting effects through the use of growth factors." IOP regulation using autologous platelet treatment OCT photo taken after PRP injection to treat hypotony in the eye of a patient after a MIGS procedure OCT image showing PRP healing effect after a microperforation Source (all): Omneya Al-Rahman, MD About the doctor Omneya Al-Rahman, MD VISSUM Institute Alicante, Spain Reference 1. Alio JL, et al. The role of "eye platelet rich plasma" (E-PRP) for wound healing in ophthal- mology. Curr Pharm Biotechnol. 2012;13:1257–65. Relevant financial interests Al-Rahman: None

• Blank Page
• Blank Page (1)